1349901-64-9

Upstream product

• 2393-23-9 4-methoxy-benzylamine 
• 1316761-67-7 C₃₃H₃₅N₇O₅ 
• 109-85-3 2-methoxyethylamine 
• 37687-24-4 diethyl 1H-pyrazole-3,5-dicarboxylate 
• 123-11-5 4-methoxy-benzaldehyde 
• 854391-95-0 bis(4-methoxybenzyl)amine hydrochloride 
• 1272403-00-5 5-bromo-N,N-bis[(4-methoxyphenyl)methyl]pyrimidin-2-amine 
• 1316761-76-8 1-(2-(bis(4-methoxybenzyl)amino)pyrimidin-5-yl)ethan-1-one 
• 1316761-74-6 1-(2-(bis(4-methoxybenzyl)amino)pyrimidin-5-yl)-2-bromoethan-1-one 
• 1316761-72-4 diethyl 1-(2-(2-(bis(4-methoxybenzyl)amino)pyrimidin-5-yl)-2-oxoethyl)-1H-pyrazole-3,5-dicarboxylate 
• 1316761-71-3 ethyl 6-(2-(bis(4-methoxybenzyl)amino)pyrimidin-5-yl)-4-oxo-4,5-dihydropyrazolo[1,5-a]pyrazine-2-carboxylate 
• 1316761-69-9 C₂₉H₂₇ClN₆O₄ 

Relevant academic research and scientific papers

NEW BICYCLIC COMPOUNDS AS PI3-K AND MTOR INHIBITORS

There is provided compounds of formula (I), wherein A1, A4, A4a,A5, B1, B1a, B2, B2a, B3, B3a, B4, B4a and R3 have meanings given in the description, and pharmaceutically-acceptable esters, amides, solvates or salts thereof, which compounds are useful in the treatment of diseases in which inhibition of a protein or lipid kinase (e.g. a PI3-K and/or mTOR) is desired and/or required, and particularly in the treatment of cancer or a proliferative disease.